Medico Intercontinental

Medico Intercontinental EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Medico Intercontinental (539938.BO) as of Oct 28, 2026 is -5.48. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 8.80 — a change of -162.27% (lower).

EV/FCF

-5.48

YoY

-162.27%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Medico Intercontinental is 2025 -5.48 . EV/FCF (Enterprise Value to Free Cash Flow) of Medico Intercontinental was 2024 8.80 . It decreases by -162.27% lower compared to the previous year.

The Medico Intercontinental EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2021
6.55 INR
Jan 1, 2022
11.45 INR
Jan 1, 2023
-3.29 INR
Jan 1, 2024
8.80 INR
Jan 1, 2025
-5.48 INR
The Medico Intercontinental EV/FCF history
YEAREV/FCFYoY
-5.48-162.27%
8.80-367.27%
-3.29-128.77%
11.45+74.85%
6.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medico Intercontinental Stock analysis

What does Medico Intercontinental do? Medico Intercontinental Ltd. generates revenue through financing, trading, and investment in shares and securities. The company provides a platform for research-based biopharmaceutical companies, focusing on product categories such as gastro, uro, nutrition, cosmetology, health devices, and hospital services. Its product portfolio includes ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, and other branded pharmaceuticals like CYCLOFACT 400, UDIFACT 150, and ZIFT SL - 250. Subsidiaries such as Evagrace Pharma Private Limited and Ritz Formulations Private Limited support its operations in the biopharmaceutical sector. The company serves biopharmaceutical firms seeking research-based solutions, with products distributed across gastroenterology, urology, nutrition, and cosmetology segments. Key brands like ALFACARE - D3, ARSUFACT Combokit, and BALOFACT target specific medical needs, while health devices and hospital-related products cater to broader healthcare markets. Subsidiaries like Sungrace Pharma Private Limited and Azillian Healthcare Private Limited contribute to the company's product development and market reach. Medico Intercontinental Ltd. monetizes its platform by facilitating trading and investment activities in securities, alongside its biopharmaceutical product sales. The company's subsidiaries manage production and distribution of branded pharmaceuticals, ensuring market presence in key healthcare segments. Products such as RELIEVE CZ, VOLIREX SPRAY, and ZYMIX SY are sold to healthcare providers and consumers in the biopharmaceutical industry. Medico Intercontinental is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medico Intercontinental stock

EV/FCF (Enterprise Value to Free Cash Flow) of Medico Intercontinental is -5.48 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Medico Intercontinental changed from 8.80 to -5.48, representing a -162.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Medico Intercontinental since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Medico Intercontinental with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medico Intercontinental

All Key Metrics — Medico Intercontinental